Coya Therapeutics, Inc. (COYA)

Market Cap	103.68M +9.3%
Revenue (ttm)	7.94M +115.4%
Net Income	-21.13M
EPS	-1.16
Shares Out	23.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	234,084
Open	5.060
Previous Close	4.870
Day's Range	4.410 - 5.100
52-Week Range	3.710 - 7.750
Beta	0.62
Analysts	Strong Buy
Price Target	15.21 (+244.12%)
Earnings Date	May 12, 2026

About COYA

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 29, 2022
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: COYA
• Website: https://www.coyatherapeutics.com

Financial Performance

In 2025, Coya Therapeutics's revenue was $7.95 million, an increase of 123.57% compared to the previous year's $3.55 million. Losses were -$21.23 million, 42.6% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for COYA stock is "Strong Buy." The 12-month stock price target is $15.21, which is an increase of 244.12% from the latest price.

Price Target

$15.21

(244.12% upside)

Analyst Consensus: Strong Buy